In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Start-Up Previews, October 2014

Executive Summary

This month’s profile group, Antibiotics: Officially Encouraged, Increasingly Precise, Still Risky, features profiles of EnBiotix, Nosopharm, and Spero Therapeutics. Plus these Start-Ups Across Health Care: Elute, Madison Vaccines, Monarch Medical Technologies, Niveus Medical, and SolaranRx.

You may also be interested in...



Monarch Medical Technologies Inc.

When it comes to effective blood glucose management, the difference is in the math, says Monarch Medical Technologies Inc. The company makes the EndoTool IV glucose management system, a patient-specific, glycemic-control computer software tool that provides individualized insulin dosing.

Elute Inc.

Elute Inc. is developing an antibiotic-releasing bone void filler designed to reduce the incidence of surgical site infections from primary and revised orthopedic procedures.

Niveus Medical Inc.

The Muscle Stimulation System 110 from Niveus Medical Inc. combines electricity with localized cooling to help prevent atrophy and associated deconditioning in hospital patients facing extended periods of bed rest.

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

IV004285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By